Pitavastatin and Liver Cancer Prevention in Obese Mice
Author Information
Author(s): Shimizu Masahito, Yasuda Yoichi, Sakai Hiroyasu, Kubota Masaya, Terakura Daishi, Baba Atsushi, Ohno Tomohiko, Kochi Takahiro, Tsurumi Hisashi, Tanaka Takuji, Moriwaki Hisataka
Primary Institution: Gifu University Graduate School of Medicine
Hypothesis
Does pitavastatin suppress liver preneoplasms induced by diethylnitrosamine in obese mice?
Conclusion
Pitavastatin effectively inhibits the early phase of obesity-related liver tumorigenesis and may help prevent liver cancer in obese individuals.
Supporting Evidence
- Pitavastatin significantly inhibited the development of hepatic premalignant lesions.
- It improved liver steatosis and activated AMPK-α protein in the liver.
- Pitavastatin decreased free fatty acid and aminotransferases levels.
- Serum levels of TNF-α and IL-6 mRNAs in the liver were decreased by pitavastatin treatment.
Takeaway
Pitavastatin is a medicine that helps lower fat in the blood and can also stop early signs of liver cancer in mice that are overweight.
Methodology
Male db/db mice were treated with diethylnitrosamine and then given different doses of pitavastatin for 14 weeks.
Limitations
The study was conducted on mice, which may not fully represent human responses.
Participant Demographics
Male C57BL/KsJ-db/db obese mice
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website